Specialty drug costs are projected to jump another 32% by 2028, according to the Pharmacy Strategies Group. While greater utilization remains the primary driver, lower-cost biosimilars can help pharmacy plans offset the increase.
Biosimilars’ overall market share increased from 22.6% in 2023 to 56.3% in 2025. Humira biosimilars led the way, growing from just 0.3% of the market to 82.4%, while Stelara biosimilars reached an 18% share in their first year of availability.
MedBen Rx makes biosimilars available for Humira, Stelara, and other high-cost biologic medications at direct-to-consumer pricing. Through our advance notice model, new biosimilars are automatically added to a plan’s formulary after notice is provided.
Clients that add biosimilars to their pharmacy plan have reduced their average monthly costs for the affected medications by an average of 78%. If you’re a client that hasn’t opted into the biosimilar program, contact your Account Management team…. and if you’re not a client but want to know more, ask your broker or MedBen Rx Marketing.